4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Regencell Bioscience Holdings Limited (RGC) operates in the Drug Manufacturers - Specialty & Generic industry and is headquartered in Causeway Bay, Hong Kong with about 10 employees. Its market capitalization is roughly $3 billion.
Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong.
Interactive charts & full statements →
| Income statement | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| Total Revenue | — | $0M | $0M | $0M |
| Operating Income (EBIT) | — | ($5M) | ($6M) | ($8M) |
| Net Income | — | ($4M) | ($6M) | ($7M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|
| Total Assets | $8M | $13M | $18M |
| Total Liabilities | $0M | $1M | $1M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive RGC viewer.
About TickerBase · Data methodology & sources